Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• Multiple Myeloma (MM) is a hematological malignancy characterized by drug resistance and dependence on high protein synthesis.
• The mammalian target of rapamycin (mTOR) pathway, comprising mTORC1 and mTORC2 complexes, regulates crucial cellular processes like protein synthesis and metabolism.
• Aberrant mTOR activation is observed in MM, contributing to cancer cell survival and therapeutic resistance.

Purpose of the Study:

• To provide a comprehensive overview of the mTOR pathway's structure, regulation, and function in the context of Multiple Myeloma.
• To highlight the role of mTOR in protein synthesis and MM pathogenesis.
• To summarize current therapeutic strategies targeting mTOR in MM and identify challenges.

Main Methods:

• This review synthesizes existing research and recent findings on the mTOR pathway.
• It discusses the structural and regulatory aspects of mTOR complexes.
• Mechanisms of mTOR involvement in protein synthesis and MM are explored.

Main Results:

• mTOR is a key regulator of protein synthesis, a hallmark of MM cells.
• Dysregulation of mTOR complexes is implicated in MM cell survival and resistance to therapies.
• Understanding mTOR regulation is crucial for developing novel MM treatments.

Conclusions:

• The mTOR pathway is a critical player in Multiple Myeloma, influencing cell survival and drug resistance.
• Targeting mTOR complexes presents a promising therapeutic avenue for MM.
• Further research is needed to overcome challenges associated with mTOR-targeted therapies in MM.